DENVER, Colo. (247marketnews.com) -- RedHill Biopharma (NASDAQ:RDHL) just sold the product that defined its U.S. commercial identity. RedHill announced it divested its remaining 70% stake in Talicia to a subsidiary of newly public Apotex Health (TSX:APTX) for $18 million in cash upfront plus up to $35 million in worldwide net sales milestones. Apotex already owned the other 30% after buying Cumberland’s (NASDAQ:CPIX) U.S. branded business earlier this year. The sale consolidates Talicia under one owner and gives RedHill the liquidity it says it needs to rebuild a larger gastrointestinal franchise.
The deal is the last chapter in a fast-moving ownership shuffle. In October 2025, RedHill formed Talicia Holdings, transferred the global Talicia business into it, and sold Cumberland a 30% stake for $4 million plus a U.S. co-commercialization partnership. Joint U.S. promotion launched in February 2026. Cumberland then agreed in April 2026 to sell its U.S. branded portfolio, including its Talicia equity, to Apotex for $100 million, a transaction that closed July 1, 2026. Eight weeks later, RedHill sold the rest.
CEO Dror Ben-Asher framed the sale as conversion of an asset into growth capital: “This transaction is a pivotal milestone for RedHill. We are converting our 70% stake in Talicia into immediate capital, significantly stronger liquidity and meaningful potential upside, while fully funding the next major step in our commercial business expansion.” He added that Apotex is “the right home to grow Talicia globally” and that the proceeds are meant to “scale RedHill’s existing gastrointestinal (GI) commercial franchise into a stronger and larger one, including new, high-value, FDA-approved product opportunities intended to drive sustained growth and accelerate our path toward operational profitability.
“Talicia is an FDA-approved all-in-one rifabutin-based therapy for H. pylori infection, a Group 1 carcinogen and a leading cause of peptic ulcers and gastric cancer. RedHill has long described it as the No. 1 branded therapy prescribed by U.S. gastroenterologists for that infection. The company keeps a late-stage pipeline outside the sold franchise—opaganib, RHB-102 (Bekinda), RHB-204, and RHB-107 (upamostat)—and says the cash now funds commercial expansion rather than another round of balance-sheet repair.For investors, the story is simple: RedHill monetized a 70% stake that had been locked inside a joint-control structure, took $18 million off the table immediately, and kept milestone upside if Apotex scales Talicia worldwide. The next test is whether that cash actually buys the “new and larger product opportunities” management promised.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.